TipRanks
Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
US Market
BCAX
Bicara Therapeutics Inc.
RESEARCH TOOLSreports
Want to see BCAX full AI Analyst Report?

Bicara Therapeutics Inc. (BCAX) Stock News & Sentiment

85 Followers
Analyst Maintains Buy Rating on Bicara Therapeutics, Keeping $35 Price Target Amid Confidence in Ficerafusp and EGFR-Bispecific Strategy
Premium
Ratings
Analyst Maintains Buy Rating on Bicara Therapeutics, Keeping $35 Price Target Amid Confidence in Ficerafusp and EGFR-Bispecific Strategy
1d ago
BCAX
Bicara Therapeutics: Buy Rating Reiterated on FICERA’s Survival Benefit in Difficult HNSCC Segment, Price Target Maintained at $30
Premium
Ratings
Bicara Therapeutics: Buy Rating Reiterated on FICERA’s Survival Benefit in Difficult HNSCC Segment, Price Target Maintained at $30
1M ago
BCAX
Bicara Therapeutics Secures Boston Headquarters Through Sublease
Premium
Company Announcements
Bicara Therapeutics Secures Boston Headquarters Through Sublease
1M ago
8K
BCAX
Bicara Therapeutics’ Earnings Call Signals Pivotal Progress
Premium
Company Announcements
Bicara Therapeutics’ Earnings Call Signals Pivotal Progress
2M ago
BCAX
BCAX Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
BCAX Earnings this Week: How Will it Perform?
2M ago
BCAX
Bicara Therapeutics reshapes board for commercialization push
Premium
Company Announcements
Bicara Therapeutics reshapes board for commercialization push
2M ago
8K
BCAX
Jeet Mukherjee Reiterates Buy on Bicara, Maintains $28 Price Target on Differentiated Ficera Profile and Upside Potential
Premium
Ratings
Jeet Mukherjee Reiterates Buy on Bicara, Maintains $28 Price Target on Differentiated Ficera Profile and Upside Potential
2M ago
BCAX
More BCAX News >

BCAX News on the Web

Bicara Therapeutics Secures Boston Headquarters Through Sublease
TipRanks News
Neutral
Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul
Insider Monkey
Neutral
Bicara Therapeutics initiated with an Outperform at BMO Capital
TipRanks News
Bullish
Analysts Conflicted on These NA Names: Bicara Therapeutics Inc. (BCAX), CoreWeave (CRWV) and Cardinal Infrastructure Group, Inc. (CDNL)
TipRanks News
Neutral
Analysts Offer Insights on NA Companies: Enhanced Group (ENHA), MNTN, Inc Class A (MNTN) and Bicara Therapeutics Inc. (BCAX)
TipRanks News
Bullish
Analysts Offer Insights on NA Companies: Smithfield Foods (SFD), Bicara Therapeutics Inc. (BCAX) and Concentra Group Holdings Parent, Inc. (CON)
TipRanks News
Bullish
Bicara Therapeutics Q2 Net Loss Expands; Phase 3 FORTIFI-HN01 Study Enrollment On Track
rttnews
Bullish
Q2 2026 Bicara Therapeutics Inc Earnings Call Transcript
GuruFocus News
Neutral

News Score - Last 7 Days

Neutral
BCAX
Sector Average
Media Buzz
This Week1 articles
Weekly Average0.5 articles
News Sentiment
This Week100%
Sector Average89%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is BCAX’s Media Buzz Sentiment?
1 articles about BCAX were published this week. In an average week, 0.5 articles are published.
    What is BCAX’s weekly average amount of articles?
    In an average week, 0.5 articles about BCAX are published.
      What is BCAX’s News Sentiment?
      100% of articles about BCAX were positive this week, compared to its sector average of 89%.
        General Stocks that are Trending in the News
        RPDRapid7
        TERATera Yatirim Menkul Degerler AS
        R2PD34Rapid7 Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.083333 Sh
        T2TD34Trade Desk, Inc. Shs A Unsponsored Brazilian Depositary Receipt Repr 0.01 Sh A
        T1AM34Atlassian Corp Shs A Unsponsored Brazilian Depository Receipt Repr 0.05 Sh A
        Showing the stocks with the most bullish news sentiment over the past week